NFE2L2 and cancer: Evidence indicates that a dysregulated NRF2/KEAP1 system, for example KEAP1 mutation[76,193] or NRF2 mutation[194], can be responsible for NRF2 overexpression in cancers leading to enhanced cellular proliferation and chemoresistance[76,187,193-195].